GNFT.PA - Genfit SA

Paris - Paris Delayed Price. Currency in EUR
15.15
+0.61 (+4.20%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close14.54
Open14.60
Bid0.00 x 0
Ask0.00 x 0
Day's Range14.60 - 15.73
52 Week Range8.90 - 23.50
Volume414,389
Avg. Volume370,498
Market Cap588.296M
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-3.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.89
  • GlobeNewswire

    GENFIT: Update on Regulatory and Clinical Activities Amid the COVID-19 Pandemic

    GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today reported an update on its regulatory and clinical activities in the context of the COVID-19 pandemic. The unprecedented spread of COVID-19 is impacting the global health and business ecosystem, GENFIT included. During this crisis, our priorities are to ensure the safety and well-being of our employees, of the patients and healthcare professionals involved in our clinical trials, as well as the integrity of our ongoing clinical trials.

  • PR Newswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT

    Pomerantz LLP is investigating claims on behalf of investors of Genfit SA ("Genfit" or the "Company") (NASDAQ: GNFT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

  • PR Newswire

    GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA ("Genfit" or the Company") (NASDAQ: GNFT). Investors who purchased Genfit securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gnft.

  • GlobeNewswire

    Correction - GENFIT: Unblinding of Phase 3 RESOLVE-IT Data Deferred

    This release is being issued to correctly state that the Phase 3 RESOLVE-IT trial remains blinded. Lille (France), Cambridge (Massachusetts, United States), February 20, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced that unblinding of the Phase 3 RESOLVE-IT data will be delayed to incorporate the latest FDA insights expected by the end of March.

  • GlobeNewswire

    GENFIT: Unblinding of Phase 3 RESOLVE-IT Data Deferred

    GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced that unblinding of the Phase 3 RESOLVE-IT data will be delayed to incorporate the latest FDA insights expected by the end of March. Topline interim results will be announced in the weeks following receipt of FDA insight.

  • Imagine Owning Genfit (EPA:GNFT) And Trying To Stomach The 76% Share Price Drop
    Simply Wall St.

    Imagine Owning Genfit (EPA:GNFT) And Trying To Stomach The 76% Share Price Drop

    While not a mind-blowing move, it is good to see that the Genfit SA (EPA:GNFT) share price has gained 23% in the last...

  • GlobeNewswire

    GENFIT: 2020 Financial Calendar

    GENFIT:  2020 Financial Calendar Lille (France), Cambridge (Massachusetts, United States), January 21, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage.

  • GlobeNewswire

    GENFIT: 2019 Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    GENFIT:  2019 Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Lille (France), Cambridge (Massachusetts, United States), January 10, 2020 – GENFIT.

  • Hedge Funds Aren’t Crazy About Genfit SA (GNFT) Anymore
    Insider Monkey

    Hedge Funds Aren’t Crazy About Genfit SA (GNFT) Anymore

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    GENFIT: Outcome of the Ordinary and Extraordinary Shareholders’ Meeting of November 27, 2019

    GENFIT: Outcome of the Ordinary and Extraordinary Shareholders’ Meeting of November 27, 2019 Lille (France), Cambridge (Massachusetts, United States), November 28, 2019 –.

  • Benzinga

    The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

  • GlobeNewswire

    GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH

    GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommends the.

  • Is Genfit SA (EPA:GNFT) A Volatile Stock?
    Simply Wall St.

    Is Genfit SA (EPA:GNFT) A Volatile Stock?

    If you own shares in Genfit SA (EPA:GNFT) then it's worth thinking about how it contributes to the volatility of your...

  • GlobeNewswire

    GENFIT Announces Results of NIS4, an Investigational Non-Invasive NASH Diagnostic, at AASLD 2019

    GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced results from a study demonstrating NIS4, an innovative non-invasive diagnostic blood test designed to diagnose nonalcoholic steatohepatitis (NASH), outperformed other non-invasive diagnostics in identifying NASH in people with type 2 diabetes.

  • Hedge Funds Are Dumping Genfit SA (GNFT)
    Insider Monkey

    Hedge Funds Are Dumping Genfit SA (GNFT)

    It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]

  • GlobeNewswire

    GENFIT Announces New Data to be Presented at AASLD Liver Meeting 2019

    GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced multiple upcoming presentations at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) to be convened in Boston, MA, November 8 -12, 2019.

  • GlobeNewswire

    GENFIT: Reports Third Quarter 2019 Financial Information

    GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced its cash position as of September 30, 2019 and revenues for the first nine months of 2019.

  • GlobeNewswire

    GENFIT: Combined Shareholders’ Meeting of November 27, 2019 – Availability of Preparatory Documents

    GENFIT: Combined Shareholders’ Meeting of November 27, 2019 – Availability of Preparatory Documents Lille (France), Cambridge (Massachusetts, United States), October 21, 2019 –.

  • GlobeNewswire

    GENFIT: Upcoming Investor Events

    GENFIT: Upcoming Investor Events Lille (France), Cambridge (Massachusetts, United States), October 7, 2019 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage.

  • Is Genfit (EPA:GNFT) A Risky Investment?
    Simply Wall St.

    Is Genfit (EPA:GNFT) A Risky Investment?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    Genfit: H1 2019 Results and R&D Pipeline Progression

    GENFIT:  H1 2019 RESULTS AND R&D PIPELINE PROGRESSION Cash position of €282 million (€207 million at December 31, 2018)USD $155 million gross proceeds from the IPO on the.

  • GlobeNewswire

    GENFIT Reinforces Corporate Leadership in the U.S.

    GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced Dr. Dean Hum’s appointment as President of GENFIT Corp. and Dr. Suneil Hosmane as Head of Global Diagnostics. Dr. Hum, who joined GENFIT in 2000 as Chief Scientific Officer will be relocating to the United States and will be based at the Cambridge, M.A. office.

  • GlobeNewswire

    Genfit: GENFIT: Dr. Carol L. Addy Joins as Chief Medical Officer

    GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced that Dr. Carol L. Addy has joined the Company as Chief Medical Officer. Dr. Addy, who is based in the Cambridge, M.A. office, will drive the medical strategy of the Company, including clinical development and medical affairs.

  • GlobeNewswire

    GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO

    GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced that its board of directors has appointed Pascal Prigent, GENFIT’s Executive Vice President of Marketing and Commercial Development, as Chief Executive Officer, following the recommendation of Jean-François Mouney, who will remain Chairman of the Board. As the Company celebrates its 20th anniversary, co-founder Jean-François Mouney has decided to focus exclusively on his role as Chairman of the Board starting September 16, 2019.

  • Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions
    Investor's Business Daily

    Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions

    The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.